Anzeige
Mehr »
Login
Donnerstag, 23.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Amazon investiert Millionen in Kernenergie - so können Sie sich früh positionieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
355 Leser
Artikel bewerten:
(1)

Transcatheter Mitral Valve Implantation Market Size Worth USD 4.67 Billion By 2027 | CAGR of 14.4%: Emergen Research

Finanznachrichten News

- Advancements in the techniques of Transcatheter Mitral Valve Implantation and substantial prevalence of Mitral Regurgitation with favorable reimbursement scenarios are expected to fuel the market growth.

VANCOUVER, BC, Sept. 23, 2020 /PRNewswire/ --

Transcatheter Mitral Valve Implantation Market Size - USD 1.82 billion in 2019, Transcatheter Mitral Valve Implantation Market Growth - CAGR of 14.4%, Transcatheter Mitral Valve Implantation Industry Trends- percutaneous transcatheter mitral valve replacement techniques, favorable investment opportunities, and technological advancements

Emergen_Research_Logo

According to the current analysis of Emergen Research, the Global Transcatheter Mitral Valve Implantation Market was valued at USD 1.82 billion in 2019 and is expected to reach USD 4.67 billion by 2027, at a CAGR of 14.4%. Rising incidences of mitral valve diseases, new pipeline devices, together with the increasing elderly population with heart conditions, is positively driving the growth of the Transcatheter Mitral Valve Implantation (repair and replacement) market in the forecast period. Mitral Regurgitation (MR) is a widespread valve disorder affecting more than 4 million people in the United States. Roughly, 250,000 cases of mitral regurgitation are recorded in the United States annually, out of which close to 50,000 patients opt for the recommended surgery. Transcatheter mitral valve replacement (TMVR) is a substitute therapeutic opportunity that has been enhanced considerably to competently treat severe mitral regurgitation in patients who are exposed to high or prohibitive surgical risks.

A practicable and comparatively safe option in patients with mitral regurgitation is called percutaneous transcatheter mitral valve replacement. In terms of safety and effectiveness, these techniques are proving to be beneficial for those patients with the potential risk of mitral valve disease. The escalating demand for this technique is enhancing the growth prospects of the global transcatheter mitral valve implantation market over the forecast period. However, cases of failed surgeries, costly target surgeries, and rigorous government rules and regulations are likely to hinder the industry growth in the forecast period.

Request free sample of this research report at: https://www.emergenresearch.com/request-sample/54

Further key findings from the report suggest

  • To develop functional (secondary) mitral regurgitation, in March 2019, MitraClip's suggestions to address the secondary MR was expanded and approved by the U.S. Food and Drug Administration (FDA). This can be administered in patients with structural changes in the heart (such as enlargement due to heart failure)
  • As mechanical values last long up to approximately 25 years post-implant/surgery, the mechanical valves segment is anticipated to dominate the industry with a market share of almost 58.3%
  • Mitral Valve Stenosis dominates the market in terms of share of approximately 44.1% in 2019. However, the Mitral Valve Regurgitation segment in the application outlook registered the highest growth rate of approximately 14.1%, owing to a rise in conditions of mitral regurgitation and due to the development of potential techniques for successful surgeries.
  • Minneapolis-based CardioMech AS, a medical device company, is developing a transfemoral, transseptally delivered mitral valve repair technology for which in August 2020, it raised funds worth USD 18.5 million for its first-in-human feasibility trial.
  • North America dominated the market in terms of revenue in 2019. Factors contributing to the largest market share (39.7%) are increasing the success rate of surgeries, high employability of technologically advanced medical heart therapy devices, and favorable compensation policies, among other encouraging scenarios.
  • Key market players profiled for this industry analysis include Abbott Laboratories, HLT Medical, Neovasc, Edward Lifesciences, Biotronik Private Limited, LivaNova, Colibri Heart Valve, Medtronic, NeoChord, MValve Technologies, Transcatheter Technologies GmbH, and Venus Medtech, among other companies.

To get leading market solutions, visit the link below: https://www.emergenresearch.com/industry-report/transcatheter-mitral-valve-implantation-market

For the purpose of this study, Emergen Research has segmented the Transcatheter Mitral Valve Implantation Market on the basis of product, application, end use, and region:

Product Outlook (Revenue in Million USD; 2017-2027)

  • Mechanical Valves
  • Bioprosthetic Tissue (Biological) Valves

Application Outlook (Revenue in Million USD; 2017-2027)

  • Mitral Valve Stenosis
  • Mitral Valve Prolapse
  • Mitral Valve Regurgitation

End Use Outlook (Revenue in Million USD; 2017-2027)

  • Hospitals
  • Ambulatory Surgical Centers
  • Diagnostic Centers
  • Other

Regional Outlook (Revenue in Million USD; 2017-2027)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
  • Middle East & Africa

Find more similar research insights by Emergen Research:

In-Vitro Diagnostics Market By Product (Reagents & Kits, Instruments), By Technique (Immunoassay, Clinical Chemistry), By Devices (Reusable IVD Devices, Disposable IVD Devices), By Application (Cancer, Infectious Diseases), By End-Use, and By Region, Forecasts to 2027

Cancer Immunotherapy Market By Technology (Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors), By Application (Head & Neck Cancer, Blood Cancers, Liver Cancer), By End-Use (Cancer Specialty Centers, Hospitals and Clinics), and By Region, Forecasts to 2027

Blockchain in Healthcare Market By Type (Permissioned/Private Blockchain, Permissionless/Public Blockchain), By Application, By End-Users (Pharmaceutical Companies, Healthcare Providers, Healthcare Payers), Forecasts to 2027

Advanced Wound Care Market By Product Type (Moist Wound Dressing, Wound Therapy Devices), By Wound Type (Surgical Wounds, Ulcers, Burns, Traumatic Wounds), By End-User (Hospitals and Clinics, Home Care Settings), and By Region, Forecasts to 2027

Cancer Tumor Profiling Market By Technique Type (Genomics, Epigenetics, Metabolomics, Proteomics), By Technology (Immunoassays, In Situ Hybridization, PCR), By Application (Research And Clinical Application), Forecasts to 2027

Craniomaxillofacial Devices Market Analysis, By Product (Cranial Flap Fixation Device, CMF Distraction Device, Drugs), By Material (Metal Based Implants, Bioabsorbable Material), By Application, By End-Use, Forecasts to 2027

About Emergen Research

At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.

With market-leading insights and an in-depth understanding of leading and niche technologies, our solutions address the most pertinent questions for your business needs. A major technological shift has been witnessed towards creating a 'Circular Economy,' fuelled by factors, such as the increased adoption of bio-based materials, along with other methods for achieving carbon neutrality. We are conversant in technologies, viz., Artificial Intelligence (AI), Augmented Reality (AR), Virtual Reality (VR), Robotic Process Automation (RPA), Smart Manufacturing, Internet of Things (IoT), Big Data Analytics, Machine learning, Nanotechnology, Edge Computing, Blockchain Technology, Cloud Computing, Vehicle Electrification, Advanced Maintenance Analytics, and Predictive Maintenance, among other prevalent and emergent technologies.

Contact Us:

Eric Lee
Corporate Sales Specialist
Emergen Research | Web: https://www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com

Read full Press Release at: https://www.emergenresearch.com/press-release/global-transcatheter-mitral-valve-implantation-market

Logo: https://mma.prnewswire.com/media/1252126/Emergen_Research_Logo.jpg

© 2020 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.